Cargando…
Treatment of ErbB2 breast cancer by mitochondrial targeting
BACKGROUND: ErbB2 breast cancer still remains an unmet need due to primary and/or acquired resistance to current treatment strategies. MEDICA compounds consist of synthetic long-chain α,ω-dicarboxylic acids previously reported to suppress breast cancer in PyMT transgenic mice. METHODS: MEDICA effica...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362624/ https://www.ncbi.nlm.nih.gov/pubmed/32695336 http://dx.doi.org/10.1186/s40170-020-00223-8 |